Targeted integration enables predictable clonal cell lines, enhancing transgene control and accelerating biopharma cell line development.
Hang Zhou
Advertisement
Hang Zhou, PhD, is head of Bioprocess Research & Development, WuXi Biologics.
Articles by Hang Zhou
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5